Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 24% ± 1% | |
GABAergic neuron | 3 studies | 18% ± 3% | |
glutamatergic neuron | 3 studies | 27% ± 1% | |
oligodendrocyte | 3 studies | 18% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 21% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 1534.42 | 459 / 459 | 100% | 31.40 | 1118 / 1118 |
esophagus | 100% | 1701.70 | 1445 / 1445 | 100% | 25.19 | 183 / 183 |
pancreas | 100% | 1224.48 | 328 / 328 | 100% | 24.59 | 178 / 178 |
prostate | 100% | 1900.17 | 245 / 245 | 100% | 30.32 | 502 / 502 |
stomach | 100% | 1533.31 | 359 / 359 | 100% | 26.92 | 286 / 286 |
uterus | 100% | 1756.81 | 170 / 170 | 100% | 31.30 | 459 / 459 |
brain | 100% | 1690.00 | 2640 / 2642 | 100% | 26.60 | 705 / 705 |
intestine | 100% | 1997.18 | 966 / 966 | 100% | 25.34 | 526 / 527 |
ovary | 100% | 1622.16 | 180 / 180 | 100% | 20.27 | 429 / 430 |
liver | 100% | 1267.58 | 226 / 226 | 100% | 18.91 | 405 / 406 |
thymus | 100% | 1294.28 | 652 / 653 | 100% | 21.72 | 604 / 605 |
adrenal gland | 100% | 1612.45 | 258 / 258 | 100% | 23.25 | 229 / 230 |
kidney | 100% | 1221.00 | 89 / 89 | 100% | 17.21 | 897 / 901 |
skin | 100% | 1720.46 | 1808 / 1809 | 100% | 29.57 | 470 / 472 |
lung | 100% | 1322.22 | 577 / 578 | 100% | 21.89 | 1151 / 1155 |
bladder | 100% | 1627.38 | 21 / 21 | 99% | 27.54 | 501 / 504 |
adipose | 100% | 1294.99 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 23.79 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 30.25 | 29 / 29 |
spleen | 100% | 1802.50 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 32.41 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 27.67 | 1 / 1 |
blood vessel | 100% | 1079.79 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 989.31 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 794.73 | 853 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 1187.65 | 910 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016925 | Biological process | protein sumoylation |
GO_1902231 | Biological process | positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage |
GO_0043488 | Biological process | regulation of mRNA stability |
GO_0006302 | Biological process | double-strand break repair |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0060887 | Biological process | limb epidermis development |
GO_1902174 | Biological process | positive regulation of keratinocyte apoptotic process |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0120186 | Biological process | negative regulation of protein localization to chromatin |
GO_0042359 | Biological process | vitamin D metabolic process |
GO_0033235 | Biological process | positive regulation of protein sumoylation |
GO_0001942 | Biological process | hair follicle development |
GO_1905168 | Biological process | positive regulation of double-strand break repair via homologous recombination |
GO_0007417 | Biological process | central nervous system development |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016363 | Cellular component | nuclear matrix |
GO_0016605 | Cellular component | PML body |
GO_1990234 | Cellular component | transferase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0019789 | Molecular function | SUMO transferase activity |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0061665 | Molecular function | SUMO ligase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PIAS4 |
Protein name | E3 SUMO-protein ligase PIAS4 (EC 2.3.2.27) (PIASy) (Protein inhibitor of activated STAT protein 4) (Protein inhibitor of activated STAT protein gamma) (PIAS-gamma) PIAS4 protein |
Synonyms | PIASG |
Description | FUNCTION: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor . Mediates sumoylation of CEBPA, PARK7, HERC2, MYB, TCF4 and RNF168 . Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53/TP53 pathway, the Wnt pathway and the steroid hormone signaling pathway . Involved in gene silencing . In Wnt signaling, represses LEF1 and enhances TCF4 transcriptional activities through promoting their sumoylations . Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation . Binds to AT-rich DNA sequences, known as matrix or scaffold attachment regions (MARs/SARs) (By similarity). Catalyzes conjugation of SUMO2 to KAT5 in response to DNA damage, facilitating repair of DNA double-strand breaks (DSBs) via homologous recombination (HR) . Mediates sumoylation of PARP1 in response to PARP1 trapping to chromatin . . |
Accessions | ENST00000262971.3 Q8N2W9 Q05DS6 |